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Allogeneic stem cell transplantation in acute
lymphoblastic leukemia and non-Hodgkin’s
lymphoma for patients ≤£ 50 years old in first
complete remission: results of the EORTC
ALL-3 trial
About 80% of adult patients withacute lymphoblastic leukemia (ALL)can obtain a complete remission
(CR),1-3 but only 30-35% of patients are
long-term leukemia-free survivors. In
recent years a number of attempts have
been made to improve the outcome by
using more intensive chemotherapy.
Remission-induction therapy (IT) has been
intensified by increasing the dose of
cyclophosphamide, cytarabine and metho-
trexate or by adding new drugs.4-7 The aim of
this approach is to destroy leukemia cells
before they develop selective drug resist-
ance. More rapid cytoreduction during the
induction treatment may not increase the
already high CR rate, but may produce
longer remissions. Consolidation with high
dose Ara-C and/or methotrexate has defi-
nitely improved the prognosis of patients
with certain subsets of ALL (mature B, T-
ALL, pro-B ALL),8 but it is of unproven or no
value in other subsets.9 Allogeneic stem cell
transplantation (allo-SCT) has been shown
to be more valuable than autologous stem
cell transplantation (auto-SCT) in younger
patients with poor prognosis ALL (Ph+
ALL).10,11 Not giving long-term maintenance
treatment is probably detrimental in certain
subgroups of ALL (common/pre-B ALL) but
randomized trials have never been per-
formed. The degree of intensity of the
maintenance regimen has no clear impact
on prognosis for the whole group of
patients with ALL, but information on its
value in subgroups of ALL is not available.12
The current policy is not to use a single pro-
tocol for all adult patients with ALL, but to
use different protocols, applied to well
defined risk groups, once the patients have
achieved complete remission.13-16 The main
goal of the ALL-317 study was to determine
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Background and Objectives. In the EORTC ALL-3 trial, the efficacy of allogeneic trans-
plantation was compared with that of autologous marrow transplantation and main-
tenance chemotherapy in patients ≤ 50 years who reached CR.
Design and Methods. Among 340 patients who entered the study, 279 were ≤ 50
years old. Out of these, 220 reached CR, 184 patients started consolidation and were
HLA typed; 68 had a donor and 116 had no sibling donor. The median follow-up was 9.5
years; 93 patients relapsed, 26 died in CR, and overall 116 patients died. Allogeneic
transplantation was performed in 47 (68%) patients with a donor while autologous
transplantation or maintenance chemotherapy was given to 84 (72%) patients without
a sibling donor. 
Results. The 6-year disease-free survival rate was similar in the groups with and with-
out  donor [38.2% (SE=5.9%) vs. 36.8% (SE=4.6%), hazard ratio 1.01, 95% CI 0.67-
1.53]. Comparing the donor group with the no donor group, the former had a lower
relapse incidence (38.2% vs. 56.3%, p=0.001), but a higher cumulative incidence of
death in CR (23.5% vs. 6.9%, p=0.0004). The 6-year survival rates were similar [41.2%
(SE=6.0%) vs. 38.8% (SE=4.6%)]. 
Interpretation and Conclusions. This trial did not show that allogeneic transplanta-
tion, when a sibling donor is available, produces a better outcome than the policy of
offering autotransplantation or chemotherapy in the absence of a donor. 
Key words: allogeneic stem cell transplantation, ALL.
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the efficacy of more intensive postremission therapy
for adult patients with ALL or non-Hodgkin’s lym-
phoma (NHL). The study protocol included high dose
Ara-C consolidation and randomization between an
intensive maintenance regimen and autologous bone
marrow transplantation. Patients with an HLA-identi-
cal family donor were assigned to undergo allogeneic
transplantation. In this intention-to-treat analysis the
efficacy of allogeneic transplantation was assessed in
comparison with that of autologous marrow trans-
plantation or maintenance chemotherapy.
Design and Methods
Study design
The EORTC ALL-3 protocol was approved by the
EORTC Protocol Review Committee and by the Ethical
Committee of each participating center. This study was
conducted from November 1986 to November 1996 in
20 European centers. Patients older than 15 years of
age and younger than 60 years of age with de novo
ALL and lymphoblastic non-Hodgkin’s lymphoma
(NHL) were included in the study. The randomization
was done centrally at the EORTC Data Center, using a
minimization technique. The stratification factors
were the center and the patient’s age. Patients with
severe heart, lung, liver, kidney or neurological dis-
eases were ineligible. The study design is presented in
Figure 1. All patients received remission induction
therapy consisting of daunomycin (45 mg/m2 on days
1, 2 and 3), cyclophosphamide (600 mg/m2 on days 1
and 8), vincristine (1.5 mg/m2 on days 1, 8, 15 and 22),
prednisone (60 mg/m2 orally in three divided doses
from day 1 to 22, then tapered over one week), and
inthrathecal methotrexate (12 mg on days 1, 8, 15 and
22). If complete remission was not achieved by day
+28 salvage therapy was administered. This salvage
therapy consisted of cytosine arabinoside (1 g/m2
given as a 2-hour infusion every 12 hours, 12 times in
6 days) and m-amsacrine (120 mg/m2 in a one-hour
infusion on days 5, 6 and 7 after the beginning of sal-
vage therapy). All patients who achieved CR were
given a course of consolidation consisting of L (E. Coli
1000 IU/kg, three times a week for two weeks), fol-
lowed by cyclophosphamide (1 g/m2 i.v. as a bolus
injection), and methotrexate (12 mg intrathecally).
Two weeks after administration of cyclophosphamide
patients received cytosine arabinoside (1 g/m2 every 12
hours) for 6 days. Patients with a sibling donor
younger than 51 years of age were assigned to under-
go allo-SCT. All patients without such a donor,
younger than 51 years, were randomized to receive
either auto-SCT or maintenance chemotherapy.
Patients not eligible for allo-SCT or for randomization
received the same maintenance chemotherapy.
Maintenance chemotherapy consisted of 2 successive
phases: a high dose and a low dose maintenance
phase. During the high maintenance phase patients
received 6 courses of 10 weeks therapy starting with
prednisone (60 mg/m2/day for 8 days) and vincristine
(1.5 mg/m2/day, days 1 and 8). Doxorubicin (60 mg/m2
on day 15) was given in courses 1, 3 and 5, while
patients received BCNU (80 mg/m2 day 15) and
cyclophosphamide (800 mg/m2 day 15) in courses 2, 4
and 6. From day 29 until day 58 treatment was 6-mer-
captopurine (90 mg/m2/day), intrathecal methotrexate
(day 29) for a total dose of 12 mg and oral methotrex-
ate (20 mg/m2/weekly). On day 64 actinomycin-D 1
mg/m2/day was administered. Two weeks after the last
course, low maintenance dose was started. This con-
sisted of oral administration of 6-mercaptopurine and
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Figure 1. EORTC
ALL-3 protocol:
study design. 
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methotrexate as in the high dose maintenance. Every
3 months vincristine (1.5 mg/m2 on days 1, 8 and 15)
and prednisone (40 mg/m2 orally days 1 to 15) were
administered.
The recommended conditioning regimen for allo-
geneic and autologous transplantation was cyclophos-
phamide (60 mg/kg on 2 consecutive days) and total
body irradiation, fractionated over three days, for a
total dose of 1200 cGy. The graft-versus-host disease
prophylaxis in most centers was cyclosporine and
short course of methotrexate.18 T-cell depletion of the
allogeneic graft was performed in 26 cases by elutria-
tion.19
The majority  of patients with Ph+ ALL were exclud-
ed after achievement of CR and were treated in a sep-
arate protocol. 
Patients
Between November 1986 and November 1996 340
patients were registered in the ALL-3 study. Of the 279
patients younger than 51 years of age, 220 (79%)
achieved CR after induction remission, with or without
salvage therapy (Figure 1). Of these patients, 36 were
off–protocol treatment due to toxicity or other rea-
sons. Of the remaining 184 patients who started the
consolidation, 68 had an HLA-identical sibling donor
(donor group) and 116 had no family donor (no donor
group) (Figure 1). In the group without a donor 38
patients were randomized to receive either auto-SCT
(n=21) or maintenance chemotherapy (n=17). An
additional 50 non-randomized patients, 40 in the no
donor group and 10 in the donor group, started the
same maintenance chemotherapy (Figure 1). Other
patients (32 in the no donor and 11 in the donor group)
received some other types of chemotherapy or no
treatment at all. The median follow-up was 9.5 years
with a range from 1 to 15 years.
Evaluation criteria
Complete remission was defined as a morphological-
ly normal marrow with less than 5% blasts, and nor-
mal peripheral blood and differential counts. Among
patients who reached CR, relapse was defined as > 5%
blasts in the bone marrow. A diagnosis of extra-
medullary relapse was based on tissue diagnosis in
case of clinical symptoms or organ or tissue infiltration
and cerebrospinal fluid cytology in case of meningeal
relapse. Risk factors were defined according to
Gökbuget et al.20
Statistical analysis
The disease-free survival (DFS) was calculated from
the date of CR until the date of first relapse or of death
in first CR. The time to relapse and time to death in CR
were calculated as the DFS; patients who died in CR
and those who relapsed were respectively censored at
that moment for these 2 analyses. By definition all
patients who died in CR were considered as cases of
treatment-related mortality (TRM). The duration of
survival was calculated from the date of CR until the
date of death; patients still alive were censored at
their last follow-up. For the comparison of the out-
come according to the randomization group (auto-SCT
versus maintenance), the starting point was the date
of randomization. 
Actuarial curves were calculated according to the
Kaplan-Meier technique.21 The standard errors (SE) of
the estimates were computed using the Greenwood
formula.21 The estimates of the incidence of relapse
and of death in CR, and their corresponding standard
errors, were obtained using the cumulative incidence
method, in which the risks of death in CR and of
relapse were considered as competing risks.21 The sta-
tistical significance of differences between actuarial
curves was tested using the two-tailed log-rank test,21
whereas the Gray test was used for the cumulative
incidences.22 A Cox proportional hazards model was
used to obtain the estimate and the 95% confidence
interval (CI) of the hazard ratio (HR) of the instanta-
neous event rate in one group compared with in
another group, as specified by a given variable, and the
Wald test was used to determine the prognostic sig-
nificance.21 This model was also used to determine the
relative prognostic importance of several factors. All
analyses were based on the intent-to-treat principle.
The database was frozen in August 2002. SAS 8.2
statistical software (SAS Institute Inc, Cary, NC, USA)
was used.
Results
Table 1 presents the patients’ characteristics accord-
ing to donor availability. The distributions of the
patients’ age and sex were similar in both groups. The
majority of patients (88%) had ALL, and a mediastinal
mass was present in more than 50% of the patients in
both groups. Immunophenotyping revealed a trend
towards a higher incidence of B-lineage ALL in the
donor group. About two-thirds of patients in both
groups fulfilled criteria for high-risk disease and in
about 40% of patients the WBC at diagnosis was high
(30×109/L). Only 6% of patients with Ph+ -ALL in both
groups were treated according to this protocol. No
cytogenetic data were available in about 30% of
patients.
Relationship between donor availability and
stem cell transplantation
In the donor group, allogeneic bone marrow trans-
plantation was performed in 47 (69%) patients (Table
2). Ten (15%) patients received maintenance chemo-
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therapy, 4 (6%) received other treatment and 7 (10%)
had no further therapy. In the no donor group, 27
(23%) patients underwent autologous bone marrow
transplantation, 57 (49%) received maintenance
chemotherapy, 16 (14%) received other maintenance
and 16 (28%) had no further therapy.
Treatment outcome for all patients
Treatment outcome for all patients is given in Table
3. In 253 (74%) out of 340 patients complete remis-
sion was achieved after remission induction and/or
salvage chemotherapy. CR after consolidation was
documented in 191 (56%), and 80 are still in continu-
B. Labar et al.
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Table 1. Patient characteristics for all eligible patients
and for patients ≤£ 50 yrs, who reached CR, according to
donor availability.
Patients ≤ 50 yrs old, who  achieved 
CR,  and started consolidation
All patients No donor Donor
N = 340 (%) N = 116 (%) N = 68 (%)
Age (yrs)
Median (range) 33 (14 – 79) 26 (14 – 50) 29.5 (14 – 48)
Age < 35 189 (56%) 79 (68%) 48 (71%)
Age 36-50 90 (27%) 37 (32%) 20 (29%)
Age > 50 61 (18%) 0 (  0%) 0 (0%)
Sex
Male 208 (61%) 82 (71%) 41 (60%)
Female 131 (39%) 34 (29%) 27 (40%)
Disease
ALL 296 (87%) 102 (88%) 60 (88%)
NHL 44 (13%) 14 (12%) 8 (12%)
Stage I/II 21 (6%) 6 (5%) 4 (6%)
Stage III/IV 23 (7%) 8 (7%) 4 (6%)
Mediastinal mass
Absent 171 (50%) 48 (41%) 29 (43%)
Present 164 (48%) 67 (58%) 39 (57%)
Immunophenotype
AUL 3 (1%) 0 (0%) 0 (0%)
B-lineage ALL 141 (41%) 45 (39%) 33 (50%)
Pro-B 20 7 4
Common ALL 49 11 16
Pre-B 14 3 6
cALL or pre-B 42 19 7
Mature-B 16 5 0
T-lineage ALL 45 (13%) 19 (16%) 13 (19%)
Pro-T 18 11 2
Pre-T 23 7 11
Mature-T 4 1 0
Bi-pheno./AML 4 (1%) 1 (1%) 0 (0%)
NHL 23 (7%) 8 (7%) 5 (7%)
N. eval./Unknown124 (36%) 43 (37%) 17 (25%)
Risk group
Standard 58 (17%) 28 (24%) 19 (28%)
High* 271 (80%) 88 (76%) 49 (72%)
WBC (×109/L)
< 30 224 (66%) 73 (63%) 38 (56%)
≥ 30 111 (33%) 43 (37%) 29 (43%)
Cytogenetics
Ph positive 30 (9%) 7 (6%) 4 (6%)
Others/Normal 195 (57%) 69 (60%) 43 (63%)
Unknown 115 (34%) 40 (34%) 21 (31%)
*: WBC 30¥109/L, age > 35 years, immunophenotyping AUL, CR reached > 4
weeks, or other criteria according to the local centers.N. eval.: not evaluated.
Table 2. Treatment applicability after consolidation for
all patients who reached CR and for patients ≤£ 50 yrs
according to donor availability.
Patients ≤ 50 yrs old, who
achieved CR,  and started
consolidation
All CRs No donor Donor
N= 253* (%) N= 116 (%) N= 68 (%)
Treatment in CR1
AutoBMT 30(12%) 27 (23%) 0 ( 0%)
AlloBMT 49(19%) 0 ( 0%) 47 (69%)
Maintenance 79(31%) 57 (49%) 10 (15%)
Other treatment 31(12%) 16 (14%) 4 ( 6%)
No other treatment 64(25%) 16 (14%) 7 (10%)
*:223 patients received consolidation; 2 patients have been allografted just after
induction.
Table 3. Treatment outcome for all patients and for
patients ≤£ 50 yrs who reached CR, and started the con-
solidation, according to donor availability.
Patients ≤ 50 yrs old, who
achieved CR, and started 
consolidation
All patients No donor Donor
N  = 340 (%) N = 116 (%) N = 68 (%)
CR after induction 228 (67%) 105 (91%) 64 (94%)
CR after induction/ 253 (74%) 116 (100%) 68 (100%)
salvage
CR after 191 (56%) 98 (85%) 60 (88%)
consolidation
DFS status*
CCR 80 (24%) 41 (36%) 24 (36%)
Relapse 131 (39%) 67 (58%) 26 (38%)
Death in CR 42 (12%) 8 (6%) 18 (26%)
Survival status
Alive 95 (28%) 44 (38%) 26 (38%)
Dead 245 (72%) 72 (62%) 42 (62%)
*: in patients who reached CR.
                                
Allo-SCT in adult ALL-NHL in first CR
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Figure 2. Disease-free
survival from random-
ization according to the
treatment arm. N =
total number of
patients; O =  observed
number of events
(relapse, death in CR).
Figure 3. Disease-free
survival from CR
according to donor
availability. N = total
number of patients; O =
observed number of
events (relapse, death
in CR).
Figure 4. Cumulative
incidence of relapse
from CR according to
donor availability. N =
total number of
patients; Or = observed
number of relapses; Od
= observed number of
deaths in CR. *:p value
was given by the Gray
test.
100
90
80
70
60
50
40
30
20
10
0
100
90
80
70
60
50
40
30
20
10
0
100
90
80
70
60
50
40
30
20
10
0
0 3 6 9 12
0 3 6 9 12
0 3 6 9 12
(years)
(years)
p* = 0.01
(years)
O N
15 24
13 21
O N
75 116
44 68
Od Nr N
8 67 116
18 26 68
Number of patients at risk
9 8 6
7 7 4
p=0.80
Hazard ratio = 0.95, 95% CI (0.66, 1.38)
Number of patients at risk
43 37 24
27 26 15
Number of patients at risk
43 37 24
27 26 15
Auto BMT
Maintenance
No donor
Donor
No donor
Donor
%
 o
f p
at
ie
nt
s 
al
iv
e 
in
 C
R
%
 o
f p
at
ie
nt
s 
al
iv
e 
in
 C
R
%
 c
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e
         
haematologica 2004; 89(7):July 2004814
B. Labar et al.
ous first complete remission; 131 patients relapsed
and 42 died in complete remission. The disease-free
survival and overall survival rates (± SE%) at 6 years
for patients who reached 1st CR were 33.5% (± 5.9%)
and 36.0% (± 5.9%), respectively. The corresponding
estimated hazard ratios with 95% confidence intervals
were 1.11 (95% CI 0-95-1.72) and 1.63 (95% CI 1.29-
-2.55), respectively. Concerning survival status, 95
(28%) patients are alive, while 245 (72%) patients
have died. A total of 45 patients were randomized to
receive either autologous bone marrow transplanta-
tion (n = 24) or maintenance chemotherapy (n = 21).
The disease-free survival was very similar for both
groups (Figure 2). The estimated hazard ratio was 1.06
(95% CI 0.50-2.23).
Effect of donor availability on outcome
The DFS was not statistically different (p=0.69)
between the donor group and the no donor group. The
6-year DFS rate for the donor group was 38.2 (± 5.9%)
versus 36.8% (± 4.6%) for the no donor group; the
estimated hazard ratio was 1.01 (95% CI 0.67-1.53)
(Figure 3).
The 6-year cumulative incidence of relapse for the
donor and no donor groups was 38.2% (± 6.0%) and
56.3% (± 4.7%), respectively (Figure 4), and the 6-year
cumulative incidence of death in CR was 23.5% (±
5.2%) and 6.9% (± 2.4%), respectively (Figure 5).
The duration of survival after CR was not signifi-
cantly different (p=0.80) between the two groups: the
estimated hazard ratio was 0.95 (95% CI 0.66-1.38)
(Figure 6). The 6-year estimate rate was 41.2% (±
6.0%) for the donor group and 38.8% (± 4.6%) for the
no donor group. Of the 47 patients in the donor group
who had an allograft, 12 died early after the transplant
and so there are no data on chronic GVHD from these
patients; among the remaining 35 patients, chronic
GvHD was reported in 12 (34%) patients: the degree of
severity was mild (n=8), moderate (n=1) or severe
(n=8).
Figure 5. Cumulative
incidence of death in
CR according to donor
availability. N = total
number of patients; Or
= observed number of
relapses; Od =
observed number of
deaths in CR. *:p value
was given by the Gray
test.
Figure 6. Survival from
CR according to donor
availability, N = total
number of patients; O =
observed number of
deaths.
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Effect of age and WBC and donor availability on
outcome
In this population of patients, all under 51 years old,
age was not of prognostic importance (p=0.34), and
did not influence the difference between the outcome
of the donor and no donor groups. The comparison of
DFS in the donor and no donor groups, adjusted for
age, remained practically unchanged: the estimated
hazard ratio was 0.96. For the risk of death in CR, the
Cox model showed that age group (HR=2.91, p=0.007)
and donor availability (HR=3.84, 95% CI 1.67-8.83,
p=0.002) were two independent prognostic factors.
Patients with initial low WBC (< 30×109/L) had a sig-
nificantly (p=0.0025) longer DFS than those with a
WBC ≥ 30×109/L: the hazard ratio was 0.59 (95% CI
0.4-0.83), and the 6-year DFS rate was 45.3% (±
4.8%) and 25.6% (± 5.2%) in the low WBC and high
WBC groups, respectively. The difference in outcome
between patients with and without a donor remained
small in each group; the estimated hazard ratio,
adjusted for WBC, remained almost unchanged (0.90),
and the 95% confidence interval was 0.62-1.31. For
the risk of relapse, the Cox model indicated that WBC
group (HR=1.95, p=0.002) and donor availability
(HR=0.58, 95% CI 0.37-0.92, p=0.02) were two inde-
pendent prognostic factors.
Risk group (high versus standard) was not of prog-
nostic importance for DFS. Differences were not
detected between the donor and no donor groups in
standard risk patients (HR=0.82, 95% CI 0.37-1.83) or
in high risk patients (HR=1.04, 95% CI 0.68-1.59). 
Discussion
This intention-to-treat analysis concerning the
whole group of ALL patients under the age of 51 years
did not prove any advantage for allogeneic transplan-
tation compared with autologous transplantation or
chemotherapy for patients treated according to EORTC
ALL-3 protocol. These results are in line with the ret-
rospective analysis of IBMTR which also showed no
difference in outcome between allografting and
chemotherapy,23,24 although some recent data from this
Registry did reveal a significantly better DFS for allo-
grafted patients younger than 30 years of age com-
pared to those receiving chemotherapy.25 The French
LALA group performed a prospective trial, similar to
ours, but in a larger cohort.26 Patients aged 15 to 40
years, in CR and with an HLA-identical sibling donor,
were assigned to be allografted. Those without a donor
were randomized to receive either autotransplantation
or maintenance therapy. According to intention-to-
treat analysis this study showed a better DFS for allo-
grafted patients compared to those treated with
chemotherapy especially in high risk patients (10-year
survival rate: 44% vs 11%). Some recent reports did
not show a better outcome for adult ALL patients with
a donor compared to those without a donor.27
Our trial confirmed28,29 that allografting is a more at
eradicating leukemia and/or lymphoblastic lymphoma
than is autografting and chemotherapy. The relapse
rate was significantly lower for the donor group than
for the no donor group (31.7% versus 50.3%).
However, the toxicity of allografting was higher than
that of other post-remission treatment options. About
30% of patients died in CR because of complications
related to allogeneic transplantation such as graft-
versus-host disease and serious infections.30,31
The known risk factors for treatment outcome, such
as tumor mass (WBC more than 30×109/L) and the
patient’s age (> 35 years of age), had no impact on the
difference in outcome according to donor availability.
Conversely, younger patients with less leukemic mass
had a better outcome than the others, and this was
independent of the availability or not of a donor. The
prognostic importance of other risk factors could not
be evaluated properly (e.g. cytogenetics, immunophe-
notyping) and there were only a very limited number
of patients in some categories (e.g.: CR reached only
after salvage [n=15]). The majority of patients with
Ph-positive ALL had been excluded after achievement
of CR and treated in another protocol. Therefore, only
11 Ph-positive ALL patients were included in the donor
vs. no donor comparison.
About 70% of patients with a donor in this trial
received an allogeneic transplant, while 30% did not
reach this part of the treatment. Most of these patients
died before transplantation because of relapse and
severe toxicity related to therapy or had become ineli-
gible for the further very intensive treatment at the
time of allotransplantation. This trial, as many oth-
ers,26,28 proved that allotransplantation is the most effi-
cient therapy in eradicating and controlling leukemia.
It might, therefore, be appropriate to perform allo-
transplantation upfront in the post-remission period,
immediately after CR has been achieved. This might
decrease treatment-related toxicity, and the drop out
of patients because of relapse. More patients with a
donor would undergo allografting in a better general
condition and in an early phase of disease. This treat-
ment strategy should be applied in high risk group of
patients and studied in a randomized prospective trial.
The graft-versus leukemia (GvL) effect has recently
been proven to occur in both T- and B-lineage ALL in
patients with acute and chronic graft-versus-host dis-
ease (GvHD).32 However, there is no evidence of a GvL
effect in ALL patients without GvHD, and this might, in
part, explain our results. It is important to stress that
the results in this study were obtained in the years
1986 to 1996. Over this long period our knowledge
and available treatments have improved substantially,
haematologica 2004; 89(7):July 2004
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especially concerning complications and supportive
care in allografted patients. Several studies have
demonstrated this, showing that transplant results
have improved recently mainly due to a decrease in
transplant-related mortality. The EBMTG clearly
showed significantly better results for patients allo-
grafted after 1991 than for those treated before.33
In conclusion, this intention-to-treat analysis did
not prove that the outcome of patients with ALL and
an HLA-identical sibling donor treated according to
EORTC ALL-3 protocol was better than that of
patients without a sibling donor. The relapse rate in
patients with a donor was significantly lower but
death in remission was significantly higher for this
group of patients. Younger patients with less leukemic
mass had the best prognosis independently of donor
availability. Improved results of allogeneic transplan-
tation are expected to reduce the treatment-related
mortality of this therapeutic approach. This effect may
alter the outcome of various treatment approaches
assessed in this study.
BL and SS contributed equally to this work. 
The manuscript is dedicated to Prof. Pierre Stryckmans who was
the co-ordinator of the EORTC ALL-3 trial.
Supported in part by grants from the National Cancer Institute
(grant numbers 5U10-CA11488-23 through 5U10-CA11488-32).
The contents of this article are solely the responsibility of the
authors and do not represent the official views of the National
Cancer Institute (Bethesda, Maryland, USA). 
We thank Saint Jude Children's Research Hospital for providing a
SAS macro allowing the analyses of competing risks. The successive
data managers of the EORTC (Mr. G. Solbu, Mrs. M. Dardenne, Mrs.
G. Eeckhout and Mrs. C. Gilotay) are also gratefully acknowledged.
Manuscript received March 9, 2004. Accepted May 10, 2004.
References
1. Copelan EA, McGuire EA. The biology
and treatment of acute lymphoblastic
leukemia in adults. Blood 1995; 85:
1151-68.
2. Laport GF, Larson RA. Treatment of adult
acute lymphoblastic leukemia. Semin
Oncol 1997;24:70-82.
3.  Hoelzer D, Gökbuget N. New approach-
es to acute lymphoblastic leukemia in
adults: where do we go? Semin Oncol
2000;27:540-9.
4. Rohatiner AZ, Bassan R, Battista R,
Barnett MJ, Gregory W, Lim J, et al. High
dose cytosine arabinoside in the initial
treatment of adults with acute lym-
phoblastic leukemia. Br J Cancer 1990;
62:454-8.
5. Weiss M, Maslak P, Feldman E, Berman E,
Bertino J, Gee T, et al. Cytarabine with
high-dose mitoxantrone induces rapid
complete remissions in adult acute lym-
phoblastic leukemia without the use of
vincristine or prednisone. J Clin Oncol
1996;14:2480-5.
6. Gökbuget N, Hoelzer D. The role of high-
dose cytarabine in induction therapy for
adult ALL. Leuk Res 2002;26:473-6.
7. Kantarjian HM, O`Brien S, Smith TL,
Cortes J, Giles FJ, Beran M, et al. Results
of treatment with hyper-CVAD, a dose-
intensive regimen, in adult acute lympho-
cytic leukemia. J Clin Oncol 2000; 18:
547-61.
8. Linker CA, Levitt LJ, O'Donnell M, Forman
SJ, Ries CA. Treatment of adult acute
lymphoblastic leukemia with intensive
cyclical chemotherapy: a follow-up
report. Blood 1991;78:2814-22.
9. Annino L, Vegna ML, Camera A, Specchia
G, Visani G, Fioritoni G, et al. Treatment
of adult acute lymphoblastic leukemia
(ALL): long-term follow-up of the
GIMEMA ALL 0288 randomized study.
Blood 2002; 99:863-71.
10. Fière D, Lepage E, Sebban C, Bouchaix C,
Gisselbrecht C, Vernant JP, et al. Adult
acute lymphoblastic leukemia: a multi-
center randomized trial testing bone
marrow transplantation as postremis-
sion therapy. J Clin Oncol 1993;11:1990-
2001.
11. Wheeler KA, Richards SM, Bailey CC,
Gibson B, Hann IM, Hill FG, et al. Bone
marrow transplantation versus chemo-
therapy in the treatment of very high-
risk childhood acute lymphoblastic
leukemia in first remission: results from
Medical Research Council UKALL X and
XI. Blood 2000;96:2412-8.
12. Ribera JM, Ortega JJ, Oriol A, Fontanillas
M, Hernandez-Rivas JM, Brunet S, et al.
Late intensification chemotherapy has
not improved the results of intensive
chemotherapy in adult acute lym-
phoblastic leukemia. Results of a
prospective multicenter randomized trial
(PETHEMA ALL-89). Haematologica
1998;83:222-30.
13. Larson RA, Dodge RK, Bloomfield CD,
Schiffer CA. Treatment of biologically
determined subsets of acute lym-
phoblastic leukemia in adults: Cancer
and Leukemia Group B studies In:
Buchner, T, Hiddeman, W, Wormann, B,
et al. Acute Leukemias VI: Prognostic
factors and treatment strategies, editors.
Springer-Verlag, Berlin; 1997. p. 677.
14. Hoelzer D, Ludwig WD, Thiel E, Gassman
W, Loffler H, Fonatsch C, et al.  Improved
outcome in adult B-cell acute lym-
phoblastic leukemia. Blood 1996; 87:
495-508.
15. Thomas DA, Cortes J, O'Brien S, Pierce S,
Faderl S, Albitar M, et al. Hyper-CVAD
program in Burkitt's-type adult acute
lymphoblastic leukemia. J Clin Oncol
1999;17:2461-7.
16. Hoelzer D, Gökbuget N, Digel W, Faak T,
Kneba M, Reutzel R, et al. Outcome of
adult patients with T-lymphoblastic
lymphoma treated according to proto-
cols for acute lymphoblastic leukemia.
Blood 2002;99:4379-85.
17. Stryckmans P, De Witte T, Marie JP, Fillet
G, Peetermans M, Bury J, et al. Therapy
of adult ALL: overview of 2 successive
EORTC studies: (ALL-2; ALL-3). The
EORTC Leukemia Cooperative Study
Group. Leukemia 1992;Suppl 2:199.
18. Storb R, Deeg HJ, Whitehead J, Appel-
baum F, Beatty P, Bensinger W, et al.
Methotrexate and cyclosporine com-
pared with cyclosporine alone for pro-
phylaxis of acute graft-versus-host dis-
ease after marrow transplantation for
leukemia. N Engl J Med 1986;314:729-
35.
19. De Witte T, Awwad B, Boezeman J,
Schattenberg A, Muus P, Raemaekers J,
et al. Role of allogenic bone marrow
transplantation in adolescent or adult
patients with acute lymphoblastic
leukaemia or lymphoblastic lymphoma
in first remission. Bone Marrow Trans-
plant 1994; 14:767-74.
20. Gökbuget N, Hoelzer D, Arnold R, Bohme
A, Bartram CR, Freund M, et al. Treat-
ment of adult ALL according to the pro-
tocols of the German Multicenter Study
Group for Adult ALL (GMALL).
Hemat/Oncol Clin North Am 2000; 14:
1307-25.
21. Klein JP, Moeschberger ML. Survival
analysis: techniques for censored and
truncated data. Statistics for Biology
and Health. Springer-Verlag, New-York.
1997. 
22. Gray RJ. A class of K-sample tests for
comparing the cumulative incidence of a
competing risk. Ann Stat 1988;16:1141-
54.
23. Horowitz MM, Messerer D, Hoelzer D,
Gale RP, Weiss A, Atkinson K, et al.
Chemotherapy compared with bone
marrow transplantation for adults with
acute lymphoblastic leukemia in first
remission. Ann Intern Med 1991;115:13-
8.
24. Zhang MJ, Hoelzer D, Horowitz MM,
Gale RP, Messerer D, Klein JP, et al. Long-
term follow-up of adults with acute
lymphoblastic leukemia in first remission
treated with chemotherapy or bone
marrow transplantation. Ann Intern Med
1995;123:428-31.
25. Oh H, Gale RP, Zhang MJ, Passweg JR,
Ino U, Murakami H, et al. Chemotherapy
versus HLA-identical sibling transplants
for adults with acute lymphoblastic
leukemia in first remission. Bone Marrow
     
haematologica 2004; 89(7):July 2004
Allo-SCT in adult ALL-NHL in first CR 
817
Transplant 1998;22:253-7.
26. Thiebaut A, Vernant JP, Degos L, Huguet
FR, Reiffers J, Sebban C, et al. Adult
acute lymphocytic leukaemia study
testing chemotherapy and autologous
and allogeneic transplantation. Follow-
up reports of the French protocol LALA
87 (Review). Hematol Oncol Clin North
Am 2000; 14:1353-66.
27. Gupta V, Yi QL, Brandwein J, Minden
MD, Schuh AC, Wells RA, et al. The role
of allogeneic bone marrow transplanta-
tion in adult patients below the age of
55 years with acute lymphoblastic
leukemia in first complete remission: a
donor vs no donor comparison. Bone
Marrow Transplant 2004;33:397-404.
28. Horowitz MM, Rowlings PA. An update
from the International Bone Marrow
Transplant Registry and the Autologous
Blood and Marrow Transplant Registry
on current activity in hematopoietic
stem cell transplantation. In: Current
Opinion in Hematology, (Stossel TP,
Goldman JM, Sander SG, editors). Rapid
Science Publishers; Philadelphia: PA.
1997. p. 395-400.
29. Uderzo C, Balduzzi A, De Lorenzo P,
Valsecchi MG, Gadner H, Klingebiel T, et
al. EBMT Pediatric Working Group; I-
BFM SG. Prospective study on allogene-
ic bone marrow transplantation (allo
BMT) versus chemotherapy (chemo) for
very high-risk (VHR) childhood acute
lymphoblastic leukaemia in first com-
plete remission. Bone Marrow
Transplant 2001;28 Suppl 1:S22-4.
30. Weiner RS. Interstitial pneumonia fol-
lowing bone marrow transplantation. In:
Recent Advances in Bone Marrow
Transplantation, UCLA Symposia on
Molecular and Cellular Biology, New
Series, Volume 53, (Gale RP, Champlin
RE, editors), Alan R. Liss, Inc., New York,
NY, USA. 1987. p. 507-23. The Advisory
Committee of the IBMTR.
31. Passweg JR, Tiberghien P, Cahn JY,
Vowals MR, Camitta BM, Gale RP, et al.
Graft versus leukemia effects in T-line-
age and B-lineage acute lymphoblastic
leukemia. Bone Marrow Transplant
1998;21:153-8.
32. Ringden O, Labopin M, Gorin NC,
Schmitz N, Schaefer UW, Prentice HG, et
al. Is there a graft-versus-leukaemia
effect in the absence of graft-versus-
host disease in patients undergoing
bone marrow transplantation for acute
leukaemia? Acute Leukaemia Working
Party of the European Group for Blood
and Marrow Transplantation. Br J Hae-
matol 2000; 111:1130-7.
33. Frassoni F, Labopin M, Gluckman E,
Prentice HG, Vernant JP, Zwaan F, et al.
Results of allogeneic bone marrow
transplantation for acute leukemia have
improved in Europe with time: a report
of  the Acute Leukemia Working Party of
the European Group for Blood and
Marrow   Transplantation (EBMT). Bone
Marrow Transplant 1996;17:13-8.
  
